Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,840.46 -36.59 (-0.46%) Bitcoin USD
65,290.29 +3,376.14 (+5.45%) CMC Crypto 200
1,344.99 +32.36 (+2.53%)
MEI Pharma, Inc. (MEIP)
| Previous close | 3.3400 |
| Open | 3.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.2500 - 3.3800 |
| 52-week range | 3.2000 - 7.9700 |
| Volume | |
| Avg. volume | 22,201 |
| Market cap | 21.654M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 1.09 |
| EPS (TTM) | 2.9800 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Nov 2023 |
| 1y target est | 23.00 |
- Business Wire
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall
- Business Wire
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had
- Business Wire
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
SAN DIEGO, April 10, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.
